key: cord-0832565-mhgnns55
authors: Yong, Ming Hui; Chan, Yvonne Fu Zi; Liu, Jiaxuan; Sanamandra, Sarat Kumar; Kheok, Si Wei; Lim, Kheng Choon; Sewa, Duu Wen
title: A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient
date: 2020-07-15
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.117035
sha: 1fd92889c6dd1ee8307652d96f010a97f8c4dbdd
doc_id: 832565
cord_uid: mhgnns55

nan

Neurological manifestations associated with severe COVID-19 infection in the current SARS-CoV-2 pandemic have been gaining attention, with encephalopathy and stroke 1,2 featuring prominently, and a recent account of acute necrotizing encephalopathy 3 . We report a rare case of a Singaporean male with severe COVID-19 pneumonia who developed Acute Hemorrhagic Leukoencephalitis (AHLE).

A 61-year-old Singaporean male with hypertension, hyperlipidemia and diabetes mellitus presented with a one-week history of fever, cough, and anosmia. On examination, he was alert with normal mental status. He was febrile at 38.0 °Celsius, respiratory rate was 20 breaths per min and oxygen saturation on ambient air was 99%. Physical examination was unremarkable except for crepitations in bilateral lung bases. Initial laboratory investigations revealed lymphopenia (0.58 x 10 9 /L). Chest radiograph showed right lower zone consolidation. SARS-CoV-2 was detected in oropharyngeal and serum samples via real time Raised intracranial pressure was managed with neuroprotective strategies and mannitol, and enoxaparin was stopped. Therapeutic plasma exchange with regional citrate anticoagulation to prevent filter clotting was initiated, but ceased after one session due to citrate toxicity.

Intravenous immunoglobulin therapy (2g/kg over 5 days) was hence administered. He achieved clearance of SARS-CoV-2 from the respiratory tract on Day 32, and methylprednisolone (1g daily for 5 days) was administered.

Five days after treatment initiation, Glasgow Coma Score (GCS) improved to E4VTM4. He was extubated, and CT brain performed 3 weeks after treatment showed stable lesions with interval improvement of the hemorrhages and mass effect. His GCS continued to improve further to E4V3M6, although he remains tetraparetic and dysphasic at this time of writing.

This is the first reported case of AHLE in a critically ill COVID-19 patient. Whilst our patient's neuroimaging findings are compatible with AHLE, other important differentials were considered. Acute necrotizing encephalopathy (ANE), which is characterized by bilateral thalamic lesions, has been reported in COVID-19 3 but is postulated to result from cytokine storm causing blood-brain barrier destruction 3, 4 . Moreover, the possibility of viralmediated endothelialitis was considered 5 . SARS-CoV-2 can potentially exploit Angiotensin Although LP was not performed, the likelihood of ongoing direct viral neuroinvasion was considered low, given that he had achieved clearance of SARs-CoV-2 from other clinical sites, and most reported cerebrospinal fluid analyses in the literature have not detected presence of the virus 2,6,7 . Furthermore, the asymmetry and entire distribution of lesions (subcortical white matter, cortex, thalami and cerebellar hemispheres), with incomplete ring contrast enhancement favored AHLE as the diagnosis 4 .

Our report serves to raise awareness of the challenges in delivering immunomodulatory treatment in severe COVID-19 disease. Considerations of thrombotic risk and steroid effects on viral clearance 8, 9 influenced our patient's treatment described above. A deeper understanding of the mechanisms of COVID-19 related inflammatory response and its contributory role to neurological insults is needed to guide optimization of therapy. Of interest is the potential role of abating the cytokine storm with monoclonal antibodies (such as Tocilizumab) 8 . Trials are ongoing, and whether they benefit the neurological outcome of COVID-19 patients remains to be seen.

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

Imaging of acute disseminated encephalomyelitis

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

COVID-19 -associated Diffuse Leukoencephalopathy and Microhemorrhages

Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection

Severe Covid-19

The authors would like to express their deep appreciation to the following individuals for their review of the manuscript and providing guidance and advice: Drs Melvin C K Tay,